Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Retrovirology

Figure 4

From: Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages

Figure 4

NanoATV treatment affects HIV-1 reverse transcriptase (RT) activity. HIV-1 RT activity was determined in treated (native ATV or nanoATV) MDM followed by HIV-1 infection at days 0, 5 or 10. HIV-1 infected cells without any treatment served as a positive control for RT activity. All samples were collected after 7 days of viral infection. Results shown are the mean of 5 replicates.

Back to article page